ReviewJournal of translational medicine2025
The airway mycobiome in chronic respiratory diseases: current advances and future frontiers.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research trends and thematic evolution of respiratory microbiota in COPD: a bibliometric study.Frontiers in medicine · 2026Pooled it
- The lung microbiome in childhood-onset severe neuromuscular disease with respiratory insufficiency: rationale, current evidence, and opportunities for oxford nanopore long-read sequencing.Molecular and cellular pediatrics · 2026Review
- Review
- Functional characterization and safety evaluation of an airway commensalFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The airway mycobiome is an important component of the respiratory microbiome and of clinical relevance, but has been largely underappreciated. Recent studies have characterized fungal community composition in the airways and elucidated its associations with the pathogenesis and progression of chronic respiratory diseases (CRDs), including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis and cystic fibrosis (CF). A systematic understanding of the composition and dynamic changes of fungal microbiota in the airways, as well as their currently known interactions with the host in CRDs, may provide comprehensive insights into the pathological mechanisms of CRDs and improve diagnostic and therapeutic strategies. In this review, we synthesize current evidence on the role of the respiratory mycobiome in CRDs, focusing on mycobiome dysbiosis during disease pathogenesis, host-fungal interactions, and associated immune modulation. Additionally, we explore future research directions, key challenges, and potential therapeutic strategies targeting the fungal microbiota. This review redefines the contribution of fungi to the pathophysiology of CRDs based on current evidence and insights.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.